Piramal Enterprises has received an approval for allotment of 5,000 Secured Redeemable Non-Convertible Debentures (NCDs), having the face value of Rs 10 lakh each, aggregating to Rs 500 crore. The meeting of committee of directors (funding) at its meeting held on January 13, 2016 has approved for the same. These NCDs shall be listed on the National Stock Exchange of India - Wholesale Debt Segment.
Piramal Enterprises is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.